Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Gotratix iconGotratixSmall moleculeNo amino acid sequence. Icon reflects category theme only.

Gotratix

Beginner tier: 200 mg, daily · 4w on / 16w off · community consensus

~2-4 hours half-life (estimated)·Oral

Also known as: A-18, Gotratix A-18, Gotratix bioregulator

Thirty-seven people. That's the entire human evidence base for Gotratix, a Khavinson-class oral peptide bioregulator extracted from young bovine muscle tissue. The St. Petersburg Institute of Bioregulation and Gerontology ran one internal study on sport veterans aged 40 to 65, and it showed improved physical performance scores at 30 days. No peer-reviewed trial has followed. Gotratix sits in the broader Khavinson bioregulator framework, which spans four decades of published research on tissue-specific short peptides. Longevity and biohacking communities use it in 30-day oral courses for muscle recovery, typically stacked alongside Epithalon or Cartalax.

What Is Gotratix?

Thirty-seven sport veterans in St. Petersburg. That's the sum total of published human data on Gotratix (designation A-18), a muscle-targeted peptide bioregulator from the Khavinson class. The compound contains short-chain peptides (2 to 7 amino acid residues, molecular weight below 10 kDa) extracted from young calf striated muscle tissue through acid hydrolysis and ultrafiltration.

The proposed mechanism is gene-level. These tissue-derived peptides are thought to cross myocyte cell membranes, enter the nucleus, and bind specific DNA sequences in gene promoter regions. That binding is claimed to normalize protein synthesis, restore cellular metabolism, and increase functional reserve capacity in muscle tissue. Related Khavinson peptides have been shown to modulate histone acetylation and DNA methylation in vitro [1].

In practice, Gotratix is an oral capsule product. Each capsule contains 200 mg of polypeptide complex. Standard protocols call for 1 to 2 capsules daily for 30 days, repeated every 4 to 6 months. No injection or reconstitution is required.

The single human study (St. Petersburg Institute, April to November 2011, n=37, ages 40 to 65) tracked step-test performance and dorsal spine mobility. Both improved vs controls. But the study is unindexed, not peer-reviewed internationally, and didn't specify the dose used. Community evidence is similarly thin: fewer than 10 English-language anecdotal reports and 5 verified buyer reviews. Most discussion happens in Russian.

The broader Khavinson bioregulator research program spans 40+ years and includes published work on Cortexin, Epithalon, and other tissue-specific peptides [2][3]. That body of work supports the general concept of short-peptide gene regulation. Gotratix itself has yet to produce the kind of dedicated clinical data that would move it beyond theoretical.

How Gotratix Works

Gotratix operates within the Khavinson bioregulator framework. The muscle-derived short peptides in this product are proposed to act as epigenetic modulators of gene expression, specific to their tissue of origin.

The mechanism starts with absorption. These small peptides (2 to 7 amino acids) survive gastric digestion due to their size. Once absorbed through intestinal epithelium, they circulate to muscle tissue. The proposed next step is entry into myocyte nuclei, where they interact with specific nucleotide sequences in gene promoter regions.

Khavinson's group has demonstrated this DNA-peptide interaction in vitro for related short peptides [1]. The binding affects histone acetylation and DNA methylation patterns, changing which genes are accessible for transcription. For muscle tissue, the claimed downstream effects include upregulation of structural proteins like myosin and actin, restoration of metabolic enzyme activity, and normalization of the balance between protein synthesis and degradation.

Mitochondrial function in muscle cells may also be affected. Supporting energy production during contraction is part of the manufacturer's proposed benefit set.

The honest assessment: these mechanisms are extrapolated from the broader Khavinson research platform. No Gotratix-specific mechanistic study has been published. The in vitro evidence on related peptides is real; the leap to Gotratix-specific myocyte gene regulation in living humans hasn't been validated.

Gotratix Benefits

  • Gotratix benefits center on muscle recovery and tissue maintenance, though the evidence base is early-stage.
  • Improved physical performance in a 37-person study of sport veterans aged 40 to 65 (St. Petersburg Institute, 2011, unindexed). Step-test scores and dorsal spine mobility both improved vs controls.
  • Reduced post-workout muscle soreness, reported consistently across the small English-language user community. Users described the effect as gradual rather than dramatic.
  • No injection required. Gotratix is an oral capsule product, which removes the reconstitution, needles, and cold storage that most peptides demand.
  • Part of a 40+ year research framework. The Khavinson bioregulator program has published indexed studies on tissue-specific gene regulation [4][2], though none specific to this compound.
  • Anecdotal injury recovery support. One verified buyer reported elbow pain improvement within two weeks of starting a course, though isolating the cause is impossible.
  • Oral dosing at 200 to 400 mg daily in 30-day courses makes compliance simple compared to injectable peptide protocols.

Gotratix: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Weak
Based on 9 key studies·Research only

No PubMed-indexed Gotratix-specific trials.

Dosing studied: 200–400 mg/day orally (1–2 caps), max 800 mg/day per manufacturer
Read the evidence (key study, limitations)

One unindexed internal study (St. Petersburg Institute, 2011, n=37 sport veterans 40–65) showed improved step-test performance and dorsal spine mobility vs controls. Broader Khavinson bioregulator research (published, indexed) supports tissue-specific short-peptide gene regulation but does not directly validate Gotratix's muscle claims.

Key Study

Internal institute report, St. Petersburg Institute of Bioregulation and Gerontology, Apr–Nov 2011 (n=37, NOT indexed in PubMed)

Limitations

Only one human study, unindexed and not peer-reviewed in international journals. No placebo-controlled RCT. Dose not specified in available report. Outcome measures limited to physical performance tests. No long-term follow-up data.

Community Experience
Weak
3.5/5
Based on <10 English-language anecdotal reports

Extremely limited English-language community.

Community dosing: 200–400 mg/day (1–2 caps daily), 30-day courses
Read the reports (what users report 4, common issues 4)

Positive anecdotal reviews online (5 stars, 5 verified buyers). Most community discussion is in Russian. Biohacking/longevity community treats it as part of multi-bioregulator stacking protocols rather than a standalone compound.

What users report (4)
  • Fuller muscle development and improved visual muscle condition
  • Reduced or eliminated post-workout muscle soreness
  • Injury recovery support (anecdotal: elbow pain improved within 2 weeks)
  • Gradual improvement in muscle endurance during training
Common issues (4)
  • Effects are gradual and difficult to isolate when stacking multiple bioregulators
  • No clear objective timeline: improvements described as subtle
  • Very limited English-language community; most discourse in Russian
  • Expensive for what is essentially a single unvalidated compound (~$5–8/day)
Partially Aligned

Both the single human study and community reports suggest modest muscle recovery and performance benefits consistent with the bioregulator mechanism, but the evidence base is too thin on both sides to call this truly aligned. Community use reflects the manufacturer's intended population (40+ adults with sarcopenia/recovery goals) and dosing is consistent with the internal study protocol.

Gotratix Dosage Guide

CommunityKhavinson Institute protocol
LevelDoseFrequency
Beginner200 mgDaily
Moderate400 mgDaily
Aggressive400 mg2x Daily
Note:

Gotratix is an oral capsule, so there's no reconstitution math to worry about. Each capsule contains 200 mg of polypeptide complex. You swallow it whole with water, 15 to 20 minutes before a meal. That timing matters for absorption.

Standard starting dose is 1 capsule (200 mg) daily for 30 days. Some practitioners use a loading protocol: 2 capsules twice daily (800 mg/day) for 10 days, then 1 to 2 capsules daily for the remaining 20 days. Don't exceed 4 capsules (800 mg) in a single day.

The thing most beginners miss with bioregulators: you won't feel anything dramatic. These aren't stimulants. Track your workout recovery scores and performance metrics before and after the course. Without a baseline, you'll never know if Gotratix did anything.

Courses repeat every 4 to 6 months. The Khavinson model claims gene expression changes persist for months post-course, so continuous daily dosing is unnecessary and just burns money. Store capsules at room temperature (15 to 25 degrees C), away from moisture and direct sunlight.

Cycling Protocol

On Period
4 weeks
Off Period
16 weeks

Standard protocol: 1-2 capsules, 1-2 times daily for 30 days. Repeat every 4-6 months. An intensive loading phase of 2 capsules twice daily for 10 days followed by standard dosing for 20 days is used by some practitioners. Take 15-20 minutes before meals for best absorption.

Calculate your Gotratix dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Gotratix Protocols by Goal

beginnerCommunity30 days
Standard course
Wk 1–4
200 mg (1 capsule) · once daily · oral

Expected: Reduced muscle soreness by weeks 2–3; modest improvement in recovery time between sessions by end of course. Effects may persist 3–6 months post-course per bioregulator model.

Monitor: No bloodwork required. Track subjective recovery scores and workout performance metrics before and after the course to assess response.

How to Use Gotratix

  1. 1
    Step 1

    Take 1 capsule (200 mg) by mouth, 15 to 20 minutes before a meal. Swallow whole with water. Do not open or crush the capsule.

  2. 2
    Step 2

    For the standard course, take 1 capsule once daily for 30 days. That's 30 capsules total, or half of a 60-capsule pack.

  3. 3
    Step 3

    For the moderate protocol, take 2 capsules (400 mg) once daily for 30 days. This doubles the daily dose and uses one full 60-capsule pack.

  4. 4
    Step 4

    For the intensive loading protocol (experienced users only), take 2 capsules (400 mg) twice daily for 10 days, then reduce to 1 to 2 capsules once or twice daily for 20 days. Maximum daily dose is 4 capsules (800 mg). Do not exceed this.

  5. 5
    Step 5

    If training around the dose, take capsules 30 to 45 minutes before a workout and again before the post-workout meal.

  6. 6
    Step 6

    Store unopened capsules at 15 to 25 degrees C, protected from moisture and direct sunlight. Shelf life is up to 2 years in original sealed packaging.

  7. 7
    Step 7

    After completing the 30-day course, wait 4 to 6 months before repeating. Athletes in heavy training blocks sometimes repeat at 3 months.

Alternative Routes

Oral capsule (standard)

200 mg per capsule; 1–4 caps/day (200–800 mg)

Take 15–20 minutes before meals. Swallow whole with water. Available in 20-cap and 60-cap packs.

Sublingual (lingual formulation)

Sublingual may improve bioavailability for intact peptide fragments: no comparative dosing data exists

Bypasses first-pass gut metabolism. Theoretically superior for peptide fragment delivery if mechanism requires intact peptides to reach myocytes via circulation. Higher cost than capsule form. No head-to-head comparison study.

Gotratix Stacking Protocols

Works With

Avoid

Immunosuppressive medications

Theoretical interaction: peptide bioactivity may interfere with immunosuppressive drug mechanisms. No formal interaction data exists. Consult prescribing physician.

Follistatin 344

Combining an epigenetic muscle bioregulator with a myostatin inhibitor introduces unpredictable additive effects on muscle protein synthesis. Both are poorly characterized in humans: combined use multiplies unknowns. Not studied together.

IGF-1 LR3

No safety data on combining Gotratix gene-regulatory mechanism with IGF-1 anabolic signaling. Both affect myocyte protein synthesis through different pathways: interaction unknown.

Estimated Cost

Generic / Research
60 caps (200 mg each) = ~$156 USD (~$5.20/day at 2 caps/day; $156/30-day course at standard dose)
Compounded
20 caps = ~$65–$80 (typical specialty bioregulator price range)

Pricing updated 2026-04-09

Gotratix Side Effects

The biggest concern with Gotratix isn't a specific adverse event. It's the absence of safety data. No formal pharmacovigilance program has tracked this compound. No clinical trial has systematically collected adverse event reports. The side effect profile is based on a handful of user reviews and the general safety record of the Khavinson bioregulator class.

Bovine protein hypersensitivity is the most concrete risk. Gotratix is extracted from young calf muscle tissue. Anyone with known sensitivity to bovine-derived proteins should avoid this product entirely. Allergic reactions (hives, respiratory symptoms, gastrointestinal distress) are theoretically possible, though documented cases across the broader bioregulator class are rare.

Gastrointestinal discomfort is the most commonly reported complaint. Bloating and mild nausea occur occasionally, particularly at the 2-capsule dose taken on an empty stomach. Adjusting timing to 15 to 20 minutes before meals typically resolves this. If symptoms persist, reducing to 1 capsule per serving is the standard recommendation.

The autoimmune question deserves attention. Gotratix contains animal-derived peptide fragments that interact with gene expression per the proposed mechanism. For individuals with active autoimmune conditions affecting muscle tissue (myositis), introducing exogenous peptides that modulate myocyte gene transcription is an unknown risk. This is listed as a contraindication by the manufacturer.

No drug interaction studies have been published. Theoretical concerns exist around immunosuppressive medications, since the peptide bioactivity could interfere with immunosuppression. Combining Gotratix with other muscle-active peptides (follistatin, IGF-1 LR3) introduces unpredictable additive effects on protein synthesis pathways.

Pregnancy and breastfeeding: no safety data exists. Not recommended. Children under 18 have not been studied.

The bottom line on tolerability: the Khavinson bioregulator class has a decades-long track record without major safety signals. But "no major signals" from a product with minimal Western-market surveillance is different from "proven safe." Anyone starting Gotratix should watch for allergic reactions in the first week and report persistent GI symptoms to a healthcare provider.

Common Issues & Solutions

No perceived effect after 30 days: Gotratix effects are often subtle and require tracking objective metrics (workout logs, recovery scores) pre- and post-course. Subjective perception of this compound is poor. Many users run 2 courses before assessing response.

GI discomfort (bloating, mild nausea): Most commonly reported with 2-cap doses on an empty stomach. Ensure pre-meal timing (15–20 min before food, not after). If persistent, reduce to 1 cap per serving.

Uncertain whether effects are from Gotratix or the stack: If running multiple Khavinson bioregulators simultaneously, it is almost impossible to isolate Gotratix effects. Consider running as a solo course first before stacking.

Bovine protein concern (vegan/vegetarian): Gotratix is derived from bovine muscle tissue (young calves). Not suitable for vegans or those with bovine protein sensitivity. No plant-derived equivalent exists for this specific compound.

Wondering when to repeat the course: Standard guidance is every 4–6 months. Some practitioners use a 3-month repeat for higher-demand periods (athletes in heavy training blocks). No data supports more frequent cycling.

Ask AI about this page

Ask AI for a second opinion on Gotratix dosing and side effects

Contraindications

  • Pregnancy and breastfeeding (no safety data available)
  • Known hypersensitivity to bovine-derived proteins or peptides
  • Active autoimmune conditions affecting muscle tissue (myositis)
  • Children under 18 (not studied in pediatric populations)
  • Individuals with severe allergic history to animal-derived supplements

Drug Interactions

  • No formal drug interaction studies have been published for Gotratix
  • Theoretical interactions with immunosuppressive medications due to peptide bioactivity
  • Use caution combining with other muscle-active peptides: additive or competing effects are possible
  • No known interactions with common supplements or standard sports nutrition products
  • Consult a healthcare provider if taking medications for neuromuscular conditions
  • Theoretical interaction: peptide bioactivity may interfere with immunosuppressive drug mechanisms. No formal interaction data exists. Consult prescribing physician.
  • Combining an epigenetic muscle bioregulator with a myostatin inhibitor introduces unpredictable additive effects on muscle protein synthesis. Both are poorly characterized in humans: combined use multiplies unknowns. Not studied together.

Product Quality

Recommended Monitoring

TestWhenTarget
Subjective recovery scoreBefore starting course, at day 15, and at day 30Not listed
Workout performance logWeekly throughout 30-day courseNot listed
Allergy symptom checkFirst 7 daysNot listed
Subjective recovery score

No objective blood test exists for Gotratix bioactivity. Tracking workout recovery (soreness scale, next-day fatigue) is the only practical way to assess response.

Workout performance log

The internal study measured step-test performance as primary outcome. Tracking similar endurance/strength metrics allows comparison to baseline.

Allergy symptom check

Bovine-derived peptide complex: rare but possible hypersensitivity reaction in first week of use.

Gotratix Before and After

Days 1-7

No noticeable effects expected. The bioregulator peptides are beginning to interact with muscle cell gene expression pathways according to the proposed mechanism.

Days 8-14

Some users anecdotally report reduced muscle fatigue and improved recovery between workouts, though placebo effects can't be ruled out given the lack of controlled trials.

Days 15-30

Proposed peak period of the treatment course. Claimed improvements in muscle endurance, reduced soreness after physical activity, and better overall muscle tone.

Weeks 5-12
post-course

Effects are said to persist after the course ends due to lasting gene expression changes. This claim is based on the broader bioregulator model rather than Gotratix-specific data.

4-6 months
repeat course

Repeated courses are recommended for cumulative benefit. The manufacturer suggests that ongoing peptide supplementation maintains optimal myocyte peptide balance over time.

What to Expect

Days 1 to 7: Nothing noticeable. The peptide fragments are absorbing and beginning to interact with myocyte gene promoter regions per the Khavinson model. No measurable physiological change happens this early. Community reports are unanimous on this; first-week expectations should be zero. Occasional mild GI adjustment is possible but rare, and typically resolves within 3 to 4 days.

Days 8 to 14: Early, subtle signals start appearing for some users. If the gene expression modulation mechanism is operative, altered transcription of muscle repair genes would be underway at this point. Some users report reduced muscle soreness after workouts and slightly better next-day energy. These improvements are described as subtle rather than dramatic. Placebo effect can't be excluded given the lack of controlled data.

Days 15 to 30: This is the proposed peak window. The manufacturer's model predicts full bioregulator effect on myocyte protein synthesis and metabolic normalization within this period. The single internal study measured its outcomes at the 30-day mark. Most anecdotal benefits cluster here: better muscle endurance, reduced soreness, improved workout capacity. Some users report improved muscle appearance and fullness.

Weeks 5 to 12 (post-course): The Khavinson model predicts that gene expression changes persist 3 to 6 months after the course ends, without continued supplementation. No Gotratix-specific data supports this claim. A handful of users note gradual decline in recovery benefits by weeks 8 to 10. Most transition to repeat-course scheduling around month 4 to 6.

4 to 6 months (repeat course): The standard repeat window. Longevity community members commonly run 2 courses per year as maintenance. Athletes may push to 2 or 3 courses per year during heavy training periods. The manufacturer frames repeated courses as maintaining optimal myocyte peptide balance over time.

Detailed Timeline: Science vs Community

Days 1–7
Science

Peptide fragments absorbing, beginning to interact with myocyte gene promoter regions per Khavinson model. No measurable physiological change expected this early.

Community

Universally reports no effects in the first week. Some users question whether capsules are working.

Days 8–14
Science

Gene expression modulation beginning: if the mechanism is operative, altered transcription of muscle repair genes would be underway. No direct evidence for this timeline.

Community

Some users report reduced muscle soreness after workouts and slightly improved next-day energy. Described as subtle: not dramatic. Placebo effect cannot be excluded.

Days 15–30
Science

Manufacturer's proposed window for full bioregulator effect on myocyte protein synthesis and metabolic normalization. The internal study measured outcomes at 30 days.

Community

Most anecdotal benefits cluster here: better muscle endurance, reduced soreness, improved workout capacity. Some report improved muscle appearance/fullness.

Weeks 5–12 (post-course)
Science

Khavinson model predicts lasting gene expression changes persist 3–6 months post-course without continued supplementation. No Gotratix-specific data for this claim.

Community

A handful of users note gradual decline in recovery benefits by weeks 8–10 post-course. Most switch to repeat-course scheduling at month 4–6.

4–6 months (repeat course)
Science

Repeated courses designed to maintain optimal myocyte peptide balance: per manufacturer protocol.

Community

Longevity users in the Khavinson community commonly run 2 courses per year as a maintenance regimen. Athletes may run 2–3 courses per year during high-training periods.

Pharmacokinetics

Half-Life
3h
Bioavailability
Oral: low to moderate for short peptides; exact bioavailability not characterized
Tmax
~1-2 hours (estimated for oral peptide capsules)
Data Confidence
low

Source: Estimated from short peptide complex kinetics; no Gotratix-specific pharmacokinetic studies published (extrapolated from Khavinson bioregulator class)

Pharmacokinetics: Active Dose Over Time

t½ = ~2-4 hours (estimated, short peptide complex)

Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

Who Should Consider Gotratix

  • Adults experiencing age-related muscle loss or sarcopenia
  • Athletes seeking muscle recovery support between training sessions
  • Individuals with occupational demands requiring sustained muscle performance
  • Older adults looking to maintain muscle function and reduce fatigue
  • Those interested in Khavinson bioregulator protocols for longevity

Related Peptides

What Changed for Gotratix

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20269 Citations

References

  1. [1]Short Peptides Regulate Gene Expression (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies (opens in a new tab)PubMed (opens in a new tab)PubMed
  3. [3]Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results (opens in a new tab)PubMed (opens in a new tab)PubMed
  4. [4]Peptide Regulation of Gene Expression: A Systematic Review (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Up to 2 years at room temperature in original sealed packaging, protected from moisture and direct sunlight
After Reconstitution
N/A: supplied as oral capsules, no reconstitution required
Temperature
15-25°C (59-77°F)

Frequently Asked Questions

No. Gotratix acts on gene expression in muscle cells; it doesn't provide amino acids for protein synthesis. Think of it as a potential adjunct to normal recovery nutrition, not a replacement. No studies compare it to protein supplementation.

The sublingual version bypasses first-pass gut digestion, which matters for peptide bioavailability. If the mechanism depends on intact peptide fragments reaching target tissue, sublingual delivery should improve efficacy. No comparative studies exist between the two forms. The sublingual version typically costs more.

Fundamentally different category. IGF-1 LR3 and follistatin have established anabolic signaling with published human or high-quality animal data. Gotratix has one unindexed study with 37 people. It aims to normalize myocyte function through gene regulation rather than drive hypertrophy through growth factor pathways.

The manufacturer targets age 40+, when sarcopenia and regulatory peptide decline kick in. Athletes aged 25-40 also use it for recovery, typically running 1-2 courses per year. No studies exist on younger populations.

Yes, but it's not comparable to a 500 mcg dose of BPC-157. Gotratix is a polypeptide complex. Not a single purified peptide; derived from bovine muscle tissue. The 200 mg represents the total mass of the peptide mixture per capsule, not a single defined active compound.